Literature DB >> 17051427

Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer.

M Kriege1, C T M Brekelmans, H Peterse, I M Obdeijn, C Boetes, H M Zonderland, S H Muller, T Kok, R A Manoliu, A P E Besnard, M M A Tilanus-Linthorst, C Seynaeve, C C M Bartels, S Meijer, J C Oosterwijk, N Hoogerbrugge, R A E M Tollenaar, H J de Koning, E J T Rutgers, J G M Klijn.   

Abstract

In the MRISC study, women with an inherited risk for breast cancer were screened by a 6-month clinical breast examination (CBE) and yearly MRI and mammography. We found that the MRISC screening scheme could facilitate early breast cancer diagnosis and that MRI was a more sensitive screening method than mammography, but less specific. In the current study we investigated the contribution of MRI in the early detection of breast cancer in relation to tumor characteristics. From November 1999 to October 2003, 1909 women were included and 50 breast cancers were detected, of which 45 were evaluable and included in the current study. We compared the characteristics of tumors detected by MRI-only with those of all other (non-palpable) screen-detected tumors. Further, we compared the sensitivity of mammography and MRI within subgroups according to different tumor characteristics. Twenty-two (49%) of the 45 breast cancers were detected by MRI and not visible at mammography, of which 20 (44%) were also not palpable (MRI-only detected tumors). MRI-only detected tumors were more often node-negative than other screen-detected cancers (94 vs. 59%; P=0.02) and tended to be more often <or=1 cm (58 vs. 31%; P=0.11). MRI was more sensitive than mammography for a wide spectrum of invasive tumor characteristics i.e., size, nodal status, histology, grade and ER status. Half of the breast cancers detected in this study were visible by MRI only and these tumors were smaller and significantly more often node-negative than other screen-detected tumors, suggesting that MRI makes an important contribution to the early detection of hereditary breast cancer.

Entities:  

Mesh:

Year:  2006        PMID: 17051427     DOI: 10.1007/s10549-006-9341-6

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  11 in total

1.  Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.

Authors:  Victor R Grann; Priya R Patel; Judith S Jacobson; Ellen Warner; Daniel F Heitjan; Maxine Ashby-Thompson; Dawn L Hershman; Alfred I Neugut
Journal:  Breast Cancer Res Treat       Date:  2010-07-20       Impact factor: 4.872

2.  Performance Measures of Magnetic Resonance Imaging Plus Mammography in the High Risk Ontario Breast Screening Program.

Authors:  Anna M Chiarelli; Kristina M Blackmore; Derek Muradali; Susan J Done; Vicky Majpruz; Ashini Weerasinghe; Lucia Mirea; Andrea Eisen; Linda Rabeneck; Ellen Warner
Journal:  J Natl Cancer Inst       Date:  2020-02-01       Impact factor: 13.506

3.  Imaging studies for the early detection of breast cancer.

Authors:  Sylvia H Heywang-Köbrunner; Ingrid Schreer; Walter Heindel; Alexander Katalinic
Journal:  Dtsch Arztebl Int       Date:  2008-08-04       Impact factor: 5.594

4.  Online tool to guide decisions for BRCA1/2 mutation carriers.

Authors:  Allison W Kurian; Diego F Munoz; Peter Rust; Elizabeth A Schackmann; Michael Smith; Lauren Clarke; Meredith A Mills; Sylvia K Plevritis
Journal:  J Clin Oncol       Date:  2012-01-09       Impact factor: 44.544

5.  Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers.

Authors:  Elizabeth A Schackmann; Diego F Munoz; Meredith A Mills; Sylvia K Plevritis; Allison W Kurian
Journal:  Fam Cancer       Date:  2013-03       Impact factor: 2.375

Review 6.  Li-Fraumeni syndrome: cancer risk assessment and clinical management.

Authors:  Kate A McBride; Mandy L Ballinger; Emma Killick; Judy Kirk; Martin H N Tattersall; Rosalind A Eeles; David M Thomas; Gillian Mitchell
Journal:  Nat Rev Clin Oncol       Date:  2014-03-18       Impact factor: 66.675

Review 7.  Contrast-enhanced MRI for breast cancer screening.

Authors:  Ritse M Mann; Christiane K Kuhl; Linda Moy
Journal:  J Magn Reson Imaging       Date:  2019-01-18       Impact factor: 4.813

8.  Impact of national guidelines on use of BRCA1/2 germline testing, risk management advice given to women with pathogenic BRCA1/2 variants and uptake of advice.

Authors:  Bettina Meiser; Rajneesh Kaur; April Morrow; Michelle Peate; W K Tim Wong; Emily McPike; Elisa Cops; Cassandra Nichols; Rachel Austin; Miriam Fine; Letitia Thrupp; Robyn Ward; Finlay Macrae; Janet E Hiller; Alison H Trainer; Gillian Mitchell
Journal:  Hered Cancer Clin Pract       Date:  2021-04-09       Impact factor: 2.857

9.  Is breast cancer prognosis inherited?

Authors:  Mikael Hartman; Linda Lindström; Paul W Dickman; Hans-Olov Adami; Per Hall; Kamila Czene
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

10.  Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI.

Authors:  J Veltman; R Mann; T Kok; I M Obdeijn; N Hoogerbrugge; J G Blickman; C Boetes
Journal:  Eur Radiol       Date:  2008-02-13       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.